Dulaglutide

Dulaglutide is a long-acting GLP-1 receptor agonist engineered as a fusion protein: two modified human GLP-1 analog peptides are covalently linked to a modified human immunoglobulin G4 (IgG4) Fc fragment. Amino-acid substitutions confer resistance to degradation by dipeptidyl peptidase-4 (DPP-4), while the large Fc-fusion structure reduces renal clearance and reduces immunogenicity, extending the half-life to roughly 5 days and enabling once-weekly subcutaneous dosing. As a GLP-1 receptor agonist it stimulates glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying, and acts on central appetite-regulation centers to increase satiety and reduce food intake.

Dulaglutide is supported by the AWARD phase 3 program for glycemic control and by a dedicated cardiovascular outcomes trial. In AWARD-6 (Dungan et al., Lancet 2014), once-weekly dulaglutide was non-inferior to once-daily liraglutide for HbA1c reduction in metformin-treated patients. The REWIND trial (Gerstein et al., Lancet 2019) enrolled 9,901 patients — a majority without established cardiovascular disease — and reported a significant reduction in major adverse cardiovascular events over a median 5.4 years, notable for its broad primary-prevention population. This evidence underlies FDA and EMA approval for type 2 diabetes. Grey-market 'research' dulaglutide is not the approved medicine and carries none of these assurances.

Educational overview only — no dosing instructions in the public hub.

The most common adverse effects are gastrointestinal — nausea, diarrhea, vomiting, and abdominal pain — generally dose-dependent and most pronounced early in treatment. Documented serious risks include acute pancreatitis, gallbladder disease, acute kidney injury (often secondary to GI-related dehydration), and hypoglycemia when combined with insulin or sulfonylureas. It carries a boxed warning for thyroid C-cell tumors based on rodent studies (human relevance unconfirmed; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2). It is a prescription medicine to be used only under medical supervision. Non-prescription, 'research use only,' or compounded products carry additional unquantified risks: uncertain dosing accuracy, impurities, and no clinical oversight.

Dulaglutide is a complex prescription biologic (a GLP-1–Fc fusion protein) whose identity, folding, and purity cannot be verified outside a licensed manufacturing and pharmacy chain. Only a pharmacy-dispensed, approved product offers assured identity and purity; grey-market vials sold as 'research grade' are of unverified composition and outside any regulatory oversight. Content here reflects the approved pharmaceutical product as studied in registered trials.

Approved prescription-only medication (FDA and EMA), marketed as Trulicity (approved 2014), requiring a physician's prescription and medical supervision. It is not a research chemical. Non-prescription or compounded dulaglutide sold outside this regulatory framework is not approved for human use and lacks quality assurance.